Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $440 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals (VRTX) and maintained a $440 price target.
February 20, 2024 | 5:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating on Vertex Pharmaceuticals and maintained a $440 price target.
The reiteration of an Overweight rating and maintenance of a high price target by a reputable analyst could positively influence investor sentiment towards VRTX, potentially leading to a short-term increase in its stock price.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90